Battelle and Canopy Growth Announce Strategic Collaboration to Advance Cannabis Research Battelle and Canopy Growth Announce Strategic Collaboration to Advance Cannabis Research
Marijuana Stocks, Finance, & Investing November 28, 2018 0
Battelle and Canopy Growth Announce Strategic Collaboration to Advance Cannabis Research
Battelle, the world’s largest nonprofit research and development organization, and Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), the world’s largest diversified cannabis company, today announced the completion of multiple fully legal cannabis imports from Canada to the United States.
Curaleaf Earnings Reports Exemplifies Current Marijuana Stock Conundrum Curaleaf Earnings Reports Exemplifies Current Marijuana Stock Conundrum
Marijuana Stocks, Finance, & Investing November 28, 2018 0
Curaleaf Earnings Reports Exemplifies Current Marijuana Stock Conundrum
Curaleaf is one of the rising stars of the U.S. marijuana industry, but its latest earnings report should…
Grown Rogue to Commence Trading on the Canadian Securities Exchange Grown Rogue to Commence Trading on the Canadian Securities Exchange
Marijuana Stocks, Finance, & Investing November 26, 2018 0
Grown Rogue to Commence Trading on the Canadian Securities Exchange
Grown Rogue International Inc. (CSE:GRIN) a seed-to-experience cannabis brand announces that the Company’s common shares are scheduled to commence trading today on the Canadian Securities Exchange under the ticker symbol “GRIN”.
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
Marijuana Stocks, Finance, & Investing November 26, 2018 0
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
GW Pharmaceuticals plc (Nasdaq: GWPH), announces positive top-line results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Dravet syndrome, a rare and severe form of childhood-onset epilepsy.
Wayland Group Enters the United Kingdom Wayland Group Enters the United Kingdom
Marijuana Stocks, Finance, & Investing November 26, 2018 0
Wayland Group Enters the United Kingdom
Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) is pleased to announce it has entered into an agreement to acquire 51% of UK based Theros Pharma Ltd., an early stage company that has successfully imported cannabis to the UK for patients with a prescription for medical cannabis.
The Two Emerging Marijuana Stocks to Watch in December — and Into 2019
Marijuana Stocks, Finance, & Investing November 26, 2018 0
Aurora Cannabis and Canopy Growth Can’t Enter the Huge U.S. Market — but These 2 Canadian Marijuana Stocks Already Have
Marijuana Stocks, Finance, & Investing November 26, 2018 0
Marijuana Stocks Are The Hottest Sector Of 2018 – Timothy Sykes
Marijuana Stocks, Finance, & Investing November 25, 2018 0
Challenges Continue to Plague Marijuana Stocks Like Canopy Growth Corp. (TSX:WEED)
Marijuana Stocks, Finance, & Investing November 25, 2018 0
